Warthin-like mucoepidermoid carcinoma of the parotid gland: Clinicopathological observation and literature review.

Warthin tumor (WT)-like mucoepidermoid carcinoma resembles the histologic pattern of WT and pathologists unaware of this possibility may misdiagnose it as WT with squamous and mucous epithelium metaplasia or WT malignant transfer into mucoepidermoid carcinoma. The present study reported a case of a 41-year-old Chinese female with a solitary mass in the left parotid gland. In this case, microscopic observation revealed prominent lymph node stroma and multiple cystic structures similar to those seen in WT. However, it lacked the two layers of oncocytic epithelial tissue characteristic of WT. Furthermore, fluorescence in situ hybridization detected MAML2 rearrangement in the case. Considering the histological findings, this case was diagnosed as WT-like mucoepidermoid carcinoma. The present case report provides pathological and clinical features to differentiate it from WT malignant transition into mucoepidermoid carcinoma, WT with squamous and mucous epithelium metaplasia and non-sebaceous lymphadenoma-like mucoepidermoid carcinoma. In conclusion, WT-like mucoepidermoid carcinoma as a special subtype of mucoepidermoid carcinoma has special histological characteristics, which required further observations and more case reports to clearly define this variant.

Spontaneous Reduction by One Electron on Water Microdroplets Facilitates Direct Carboxylation with CO2.

Recent advances in microdroplet chemistry have shown that chemical reactions in water microdroplets can be accelerated by several orders of magnitude compared to the same reactions in bulk water. Among the large plethora of unique properties of microdroplets, an especially intriguing one is the strong reducing power that can be sometimes as high as alkali metals as a result of the spontaneously generated electrons. In this study, we design a catalyst-free strategy that takes advantage of the reducing ability of water microdroplets to reduce a certain molecule, and the reduced form of that molecule can convert CO2 into value-added products. By spraying the water solution of C6F5I into microdroplets, an exotic and fragile radical anion, C6F5I•-, is observed, where the excess electron counter-intuitively locates on the σ* antibonding orbital of the C-I bond as evidenced by anion photoelectron spectroscopy. This electron weakens the C-I bond and causes the formation of C6F5-, and the latter attacks the carbon atom on CO2, forming the pentafluorobenzoate product, C6F5CO2-. This study provides a good example of strategically making use of the spontaneous properties of water microdroplets, and we anticipate that microdroplet chemistry will be a green avenue rich in new opportunities in CO2 utilization.

Retracted Article: CircRNA PVT1 modulates cell metastasis via the miR-181a-5p/NEK7 axis and cisplatin chemoresistance through miR-181a-5p-mediated autophagy in non-small cell lung cancer.

In the initiation and evolution of human cancers, circular RNAs (circRNAs) act as crucial regulators. The aim of this report was to ascertain the functional mechanisms of circRNA plasmacytoma variant translocation 1 (circPVT1) in the metastasis and chemoresistance of non-small cell lung cancer (NSCLC). The levels of circPVT1, microRNA-181a-5p (miR-181a-5p) and non-inherited maternal antigens-related kinase 7 (NEK7) were examined via quantitative real-time polymerase chain reaction (qRT-PCR). The levels of the associated proteins were determined through western blot. Cell counting kit-8 (CCK-8) and flow cytometry were used to assess the half inhibitory concentration (IC50) of cisplatin and cell apoptosis, respectively. Cell invasion was detected by transwell assay. A dual-luciferase reporter assay and RNA immunoprecipitation (RIP) were used to confirm the target relation. The impact of circPVT1 on cisplatin chemoresistance in vivo was investigated using xenograft experiments. CircPVT1 and NEK7 were up-regulated and miR-181a-5p was down-regulated in NSCLC. CircPVT1 knockdown refrained the cisplatin chemoresistance and metastasis of NSCLC cells. MiR-181a-5p was a target of circPVT1 and circPVT1 inhibition alleviated the effects of a miR-181a-5p inhibitor on NSCLC cells. The decrease of circPVT1 accentuated the si-NEK7-inhibited metastasis by the miR-181a-5p/NEK7 axis and relieved the 3-methyladenine (3-MA)-promoted cisplatin chemoresistance by miR-181a-5p-mediated autophagy. Down-regulation of circPVT1 facilitated the cisplatin sensitivity of NSCLC cells in vivo. Due to the modulation of cell metastasis via the miR-181a-5p/NEK7 axis and cisplatin chemoresistance by miR-181a-5p-mediated autophagy in NSCLC, circPVT1 might act as an appreciable therapeutic marker for NSCLC.

A case of matrix-producing carcinoma of the breast with micoglandular adenosis and review of literature.

Matrix-producing carcinoma (MPC) of the breast is an extremely rare variant of metaplastic breast carcinoma that contains a mixture of epithelial and mesenchymal elements. As overt carcinoma with direct transition to a cartilaginous and/or osseous stromal matrix cells, MPC is of no spindle cells between those two elements. This is the case of a 43 year-old female patient with MPC which coexisted with microglandular adenosis (MGA), atypical MGA (AMGA) and carcinoma in situ arising in MGA (MGACA in situ). MGA is a rare, infiltrative, benign lesion of the breast with an indolent clinical course. Histological evidence of carcinoma arising from MGA has previously been documented. MPC arising in MGA is an extremely rare subtype of breast carcinoma and has been seldom detailed described in the previous studies. This report highlights one such case with cytomorphological and histopathological correlation, along with a review of pertinent literature and differential diagnosis.

Expression and prognostic significance of VEGFR-2 in breast cancer.

Breast cancer is one of the most common cancers among women in the world. Vascular endothelial growth factor receptor 2 (VEGFR-2) was not only found to play a key role in the development of tumor angiogenesis, but has also been located in tumor cells of a variety of tumors. This study investigated the expression pattern of VEGFR-2 in breast cancer tissue specimens in order to evaluate the role of VEGFR-2 in the prognosis of breast cancer. Expression and localization of VEGFR-2 in tumor cells of breast cancer specimens from 98 invasive breast cancer patients were determined by immunohistochemistry. The relationships between VEGFR-2 expression and clinicopathological features were also analyzed. The results showed that VEGFR-2 expression correlated positively with lymph node (LN) metastasis of breast cancer. Patients with high expression of VEGFR-2 had a significantly worse OS. It was also observed that the expression of epithelial-mesenchymal transition (EMT) marker, including Twist1 and Vimentin, was higher in the tumors with higher VEGFR-2 expression, while the E-cadherin expression was lower in the same tumors, suggesting that VEGFR-2 may serve as a possible mediator of EMT in breast cancer.

Analysis of DNA methylation status of the promoter of human telomerase reverse transcriptase in gastric carcinogenesis.

BACKGROUND AND AIMS: Telomerase is expressed in normal somatic cells and reactivated in majority of tumor cells. Human telomerase reverse transcriptase (hTERT), a catalytic subunit of telomerase, is a rate-limiting factor of telomerase activity. Evidence has shown that gastric cancer is the result of genetics and epignomics. DNA methylation is one of the most important research fields in epigenomics. It is one of the mechanisms resulting in gene silencing in carcinogenesis. METHODS: Genomic DNAs were extracted from normal gastric mucosa, precancerous lesions and gastric cancer samples and were modified by sodium bisulfite. The modified genomic DNAs were amplified by PCR with primers that did not contain CpG sites. Each PCR product was sequenced. By matching the sequencing results and the original sequence, the status of each sample was obtained. PCR was carried out to identify hTERT expression. RESULTS: The promoter of hTERT in gastric cancer was more methylated than in the precancerous lesions and normal gastric mucosa (p<0.05). hTERT was absent in normal gastric mucosa and its positive rate was higher in gastric cancer than in precancerous lesions (p<0.05). CONCLUSIONS: hTERT promoter in gastric cancer was more methylated than in the precancerous lesions and normal gastric mucosa. This may suggest that the degree of methylation of the hTERT promoter was increased during gastric carcinogenesis and may be a potential biological maker in early diagnosis of gastric cancer. During gastric carcinogenesis, expression of hTERT was increased. This may suggest that methylation of hTERT may influence expression of hTERT.

[Preliminary study on the alternative splicing pattern of human telomerase reverse transcriptase gene during gastric carcinogenesis].

OBJECTIVE: To investigate the changes of the human telomerase reverse transcriptase gene (hTERT) alterative splicing pattern in gastric carcinogenesis. METHODS: Three alternative splicing sites (alpha, beta, gamma) were selected to design primers. The expression of eight hTERT alternative splicing variants (ASVs) in normal gastric mucosa, precancerous lesions and gastric cancer was detected by semi-nested reverse transcription-polymerase chain reaction (RT-PCR). The expression of beta site-remaining ASV (beta (+) hTERT mRNA) in precancerous lesions and gastric cancer tissues was detected by SYBR green real-time RT-PCR. RESULTS: The positive rate of alpha(+) beta(+)gamma(+) hTERT mRNA was significantly higher in gastric cancer than in precancerous lesions and normal mucosa (94.7% vs. 40.0% and 0, P<0.05). The positive rates of other ASVs were not different among the three groups. The positive rates of beta deletion ASV were 72.2% in normal mucosa, 95.0% in precancerous lesions and 100.0% in gastric cancer. The mRNA level of beta(+) hTERT was 5.49 folds higher in gastric cancer than in precancerous lesions. CONCLUSION: The hTERT alternative splicing pattern changes during gastric carcinogenesis. The beta(+) hTERT mRNA is expressed increasingly during gastric carcinogenesis and may provide useful information for diagnosis of gastric cancer or precancerous lesions.

Changes of the alternative splicing variants of human telomerase reverse transcriptase during gastric carcinogenesis.

OBJECTIVE: We attempted to reveal the changes of the human telomerase reverse transcriptase (hTERT) alternative splicing pattern in gastric carcinogenesis. METHODS: Three alternative splicing sites (alpha, beta, gamma) were selected and designed PCR primer. The expression of 8 hTERT alternative splicing variants (ASVs) in normal gastric mucosa, precancerous lesions and gastric cancer were detected by seminested RT-PCR. The expression of beta-site remaining ASV (beta(+) ASV) in specimens of precancerous lesions and specimens of gastric cancer was detected by SYBER Green real-time PCR. RESULTS: The positive rate of alpha(+)beta(+)gamma(+) ASV was significantly higher in gastric cancer than in precancerous lesions and normal mucosa (94.7 vs. 40.0% and 0%, p < 0.05). The positive rates of other ASVs were not different among the 3 groups (p > 0.05). The positive rates of beta(+) ASVs (including alpha(+)beta(+)gamma(+) ASV, alpha-deletion ASV, gamma-deletion ASV, alphagamma-deletion ASV) were 11.1% in normal mucosa, 40.0% in precancerous lesions and 94.7% in gastric cancer (p < 0.05). SYBR Green real-time RT-PCR showed that the expression level of beta(+) ASV was 6.99 times higher in gastric cancer than in precancerous lesions. CONCLUSION: hTERT alternative splicing pattern is different during gastric carcinogenesis. beta(+) ASV was widely expressed in gastric carcinogenesis and may provide some information for diagnosis of gastric cancer or precancerous lesions.

[Changes of alternative splicing variants of human telomerase reverse transcriptase during gastric carcinogenesis].

BACKGROUND & OBJECTIVE: The expression of human telomerase reverse transcriptase (hTERT) is positively correlated to the activity of telomerase. Alternative splicing exists in the transcription of hTERT and special splicing patterns may change during tumor progression. This study was to reveal the changes of hTERT alterative splicing pattern in gastric carcinogenesis. METHODS: Three alternative splicing sites (alpha, beta, gamma) were selected to design primers. The expression of eight hTERT alternative splicing variants (ASVs) in 18 specimens of normal gastric mucosa, 20 specimens of precancerous lesions and 19 specimens of gastric cancer was detected by semi-nested reverse transcription-polymerase chain reaction (RT-PCR). The expression of beta site-remaining ASV (beta+ hTERT mRNA) in precancerous lesions and gastric cancer tissues was detected by SYBR Green real-time RT-PCR. RESULTS: The positive rate of alpha+beta+gamma+ hTERT mRNA was significantly higher in gastric cancer than in precancerous lesions and normal mucosa (94.7% vs. 40.0% and 0, P<0.05). The positive rates of other ASVs were not different among the three groups. The positive rates of beta-deletion ASV were 72.2% in normal mucosa, 95.0% in precancerous lesions and 100.0% in gastric cancer. The positive rates of beta+ hTERT mRNA (including alpha+beta+gamma+ hTERT mRNA, alpha-deletion ASV, gamma-deletion ASV, alphagamma-deletion ASV) were 11.1% in normal mucosa, 40.0% in precancerous lesions and 94.7% in gastric cancer (P<0.05). The mRNA level of beta+ hTERT was 6.99 times higher in gastric cancer than in precancerous lesions. CONCLUSIONS: hTERT alternative splicing pattern changes during gastric carcinogenesis. beta+ hTERT mRNA is expressed increasingly during gastric carcinogenesis and may provide useful information for diagnosis of gastric cancer or precancerous lesions.